Psychiatry - UNC School of Medicine
Document Actions
Child and Adolescent Research
IMPROVING METABOLIC PARAMETERS OF ANTIPSYCHOTIC CHILD TREATMENT – Multi-site Study (IMPACT-MS)
The goal of this study is to find better treatments for children who have gained weight while taking antipsychotic medication.
Ages: 8 - 17 years
PREVENT: Metformin Mitigation Of Atypical Antipsychotic-Induced Metabolic Dysregulation In Adolescent Youths
The purpose of this study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount of weight gain and the metabolic changes typically seen with second-generation antipsychotic medication.
Ages: 10 - 17 years
CONTE: Mapping Adolescent Brain Function
This study is looking at the risk factors of Schizophrenia. We will be looking at how the brain works and grows during adolescence using brain imaging. We are interested in children that are "at risk", meaning that they have a first-degree relative (mother, father, brother or sister) that has been diagnosed with Schizophrenia or Schizoaffective Disorder.
Ages 9-18
MAPS: Mapping of Brain Function in Schizophrenia
The purpose of this study is to use magnetic resonance imaging (MRI) and or electrophysiological recording (EEG) to evaluate brain function, structure and/or chemistry. Read more >>
Ages: 9-60, length of symptoms or criteria: diagnosed with schizophrenia or schizoaffective disorder, and taking an atypical antipsychotic.
ZIP: Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk
The goal of the ZIP study is to better understand the treatment of Basic Symptoms. All of the participants in this study have a 50 % chance that they will receive medication. Each individual is randomly assigned to either receive medication or not. Read more >>
Ages: 16-40
NAPLS II: Predictors and Mechanisms of Conversion to Psychosis
The purpose of this study is to increase our ability to identify patients at clinical high-risk for the development of a psychotic disorder and to investigate neurobiological changes that underlie the emergence of a psychotic disorder. Read More>>
Ages: 12-35